董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles K. Gayer | -- | Director and Chief Executive Officer, President | -- | 962.79万美元 | 117.04 | 2026-01-01 |
| Steven Frank | -- | Director | -- | 39.65万美元 | 4.63 | 2026-01-01 |
| Theresa M. Heggie | -- | Independent Director | -- | 40.17万美元 | 23.16 | 2026-01-01 |
| A. Machelle Sanders | -- | Independent Director | -- | 38.53万美元 | 20.35 | 2026-01-01 |
| Vincent J. Milano | -- | Independent Director | -- | 40.37万美元 | 30.49 | 2026-01-01 |
| Alan G. Levin | -- | Independent Director | -- | 39.75万美元 | 30.55 | 2026-01-01 |
| Steven K. Galson | -- | Independent Director | -- | 38.56万美元 | 27.71 | 2026-01-01 |
| Amy E. McKee | -- | Independent Director | -- | 39.00万美元 | 24.20 | 2026-01-01 |
| Jon P. Stonehouse | 男 | Director | 64 | 1295.11万美元 | 551.65 | 2026-01-01 |
| Nancy J. Hutson | 女 | Chairman of the Board | 76 | 68.29万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Babar Ghias | 男 | Chief Financial Officer,Principal Accounting Officer and Head of Corporate Development | 47 | 未披露 | 未持股 | 2026-01-01 |
| Charles K. Gayer | -- | Director and Chief Executive Officer, President | -- | 962.79万美元 | 117.04 | 2026-01-01 |
| Helen M. Thackray | -- | Chief Research and Development Officer | -- | 433.96万美元 | 104.46 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Charles K. Gayer
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Steven Frank
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Theresa M. Heggie
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- A. Machelle Sanders
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Vincent J. Milano
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alan G. Levin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Steven K. Galson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Amy E. McKee
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jon P. Stonehouse
-
Jon P. Stonehouse，自2014年12月起担任董事会成员。2007年1月以来，他担任BioCryst Pharmaceuticals， Inc.（一家公共生物制药公司）的首席执行官和董事会成员。2007年7月以来，他还担任BioCryst的总裁。2002年3月至2006年12月，他曾担任Merck KGaA（一家制药公司）的多个职位，包括2002年7月至2006年12月担任企业发展高级副总裁，2002年3月至2006年12月担任全球许可和业务发展与整合副总裁。2008年11月以来，他还担任Precision Biosciences， Inc.（私人生物技术公司）的顾问委员会成员。他持有Minnesota大学的化学学士学位。
Jon P. Stonehouse,has served as a member of Board of Directors since December 2014. Since January 2007 Mr. Stonehouse has served as the Chief Executive Officer and a member of the Board of Directors of BioCryst Pharmaceuticals, Inc., a public biopharmaceutical company. Since July 2007 he has also served as President of BioCryst. From March 2002 to December 2006 Mr. Stonehouse served in various positions at Merck KGaA, a pharmaceutical company, including as Senior Vice President of Corporate Development from July 2002 to December 2006 and Vice President of Global Licensing and Business Development and Integration from March 2002 to December 2006. Since November 2008 Mr. Stonehouse has also served as a member of the Advisory Board of Precision Biosciences, Inc., a private biotechnology company. Mr. Stonehouse received his B.S. in Chemistry from the University of Minnesota. - Jon P. Stonehouse，自2014年12月起担任董事会成员。2007年1月以来，他担任BioCryst Pharmaceuticals， Inc.（一家公共生物制药公司）的首席执行官和董事会成员。2007年7月以来，他还担任BioCryst的总裁。2002年3月至2006年12月，他曾担任Merck KGaA（一家制药公司）的多个职位，包括2002年7月至2006年12月担任企业发展高级副总裁，2002年3月至2006年12月担任全球许可和业务发展与整合副总裁。2008年11月以来，他还担任Precision Biosciences， Inc.（私人生物技术公司）的顾问委员会成员。他持有Minnesota大学的化学学士学位。
- Jon P. Stonehouse,has served as a member of Board of Directors since December 2014. Since January 2007 Mr. Stonehouse has served as the Chief Executive Officer and a member of the Board of Directors of BioCryst Pharmaceuticals, Inc., a public biopharmaceutical company. Since July 2007 he has also served as President of BioCryst. From March 2002 to December 2006 Mr. Stonehouse served in various positions at Merck KGaA, a pharmaceutical company, including as Senior Vice President of Corporate Development from July 2002 to December 2006 and Vice President of Global Licensing and Business Development and Integration from March 2002 to December 2006. Since November 2008 Mr. Stonehouse has also served as a member of the Advisory Board of Precision Biosciences, Inc., a private biotechnology company. Mr. Stonehouse received his B.S. in Chemistry from the University of Minnesota.
- Nancy J. Hutson
-
Nancy J. Hutson，女，博士，自2009年以来，她一直是董事会的成员。并且是Endo的研究与发展委员会的主席和Endo的薪酬委员会成员，提名和治理委员会和事务委员会成员。在2006年，她在25年的各种研究和领导职位之后，从Pfizer公司退休。最近她担任Pfizer全球研发高级副总裁，和Pfizer制药研发网站董事，被称为格罗顿/新伦敦实验室，在Pfizer制药公司最大的研发中心。在Pfizer，她带领4500个同事主要是科学家，管理预算超过10亿美元。目前她是Cubist Pharmaceuticals和 BioCryst Pharmaceuticals公司的董事，并服务于康涅狄格州的计划生育委员会。她获得Illinois Wesleyan University的一般生物学学士学位，以及Vanderbilt University的生理学和生物化学博士学位。
Nancy J. Hutson, Ph.D.,has been a member of the Board of Directors since the Company's inception in February 2014 and is Chairman of Endo's Compliance Committee and a member of Endo's Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. Pfizer in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a Director of BioCryst Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until January 2015 and from March 2009 until February 2014 was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage. - Nancy J. Hutson，女，博士，自2009年以来，她一直是董事会的成员。并且是Endo的研究与发展委员会的主席和Endo的薪酬委员会成员，提名和治理委员会和事务委员会成员。在2006年，她在25年的各种研究和领导职位之后，从Pfizer公司退休。最近她担任Pfizer全球研发高级副总裁，和Pfizer制药研发网站董事，被称为格罗顿/新伦敦实验室，在Pfizer制药公司最大的研发中心。在Pfizer，她带领4500个同事主要是科学家，管理预算超过10亿美元。目前她是Cubist Pharmaceuticals和 BioCryst Pharmaceuticals公司的董事，并服务于康涅狄格州的计划生育委员会。她获得Illinois Wesleyan University的一般生物学学士学位，以及Vanderbilt University的生理学和生物化学博士学位。
- Nancy J. Hutson, Ph.D.,has been a member of the Board of Directors since the Company's inception in February 2014 and is Chairman of Endo's Compliance Committee and a member of Endo's Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. Pfizer in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a Director of BioCryst Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until January 2015 and from March 2009 until February 2014 was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage.
高管简历
中英对照 | 中文 | 英文- Babar Ghias
Babar Ghias加盟该公司的出身是AvenCell Therapeutics，Inc.（“AvenCell”），这是一家临床阶段的CAR-T公司，专注于血液系统恶性肿瘤，他自2022年起担任该公司的首席财务官。在加入AvenCell之前，2017年至2022年，Ghias先生在全球生物技术开发公司Paragon Biosciences，LLC（“Paragon”）担任投资和投资组合管理执行副总裁。他还曾担任多家Paragon投资组合公司的首席财务和运营官。在Paragon，他推出了四家专注于罕见病的生物技术公司，从早期临床到成功商业推出。从2014年到2017年，Ghias先生在一家特种罕见病公司Marathon Pharmaceuticals，LLC担任首席财务官和企业发展主管，在那里他为公司的商业发布做好了准备，并领导了该公司的成功出售。在其职业生涯的早期，十多年来，他是一名投资银行家，曾在瑞士信贷担任并购团队的高级成员，为医疗保健和生命科学行业的客户和董事会提供战略建议。Ghias先生在巴基斯坦拉合尔管理科学大学获得经济学学士学位，并在圣路易斯华盛顿大学以优异成绩获得工商管理硕士学位。
Babar Ghias,joins the Company from AvenCell Therapeutics, Inc. ("AvenCell"), a clinical-stage CAR-T company focused on hematologic malignancies, where he served as Chief Financial Officer since 2022. Prior to joining AvenCell, from 2017 to 2022, Mr. Ghias was Executive Vice President of Investments and Portfolio Management at Paragon Biosciences, LLC ("Paragon"), a global biotech development firm. He also served as Chief Financial and Operating Officer for several Paragon portfolio companies. At Paragon, he launched four biotechnology companies focused on rare diseases from early clinical to successful commercial launch. From 2014 to 2017, Mr. Ghias served as Chief Financial Officer and Head of Corporate Development at Marathon Pharmaceuticals, LLC, a specialty rare disease company, where he prepared the company for a commercial launch and led the successful sale of the firm. Earlier in his career, for over a decade, he was an investment banker who served as a senior member of the mergers and acquisitions team at Credit Suisse, providing strategic advice to clients and boards of directors in the healthcare and life sciences industries. Mr. Ghias received his B.S. degree in Economics from Lahore University of Management Sciences in Pakistan and earned his M.B.A. with honors from Washington University in St. Louis.- Babar Ghias加盟该公司的出身是AvenCell Therapeutics，Inc.（“AvenCell”），这是一家临床阶段的CAR-T公司，专注于血液系统恶性肿瘤，他自2022年起担任该公司的首席财务官。在加入AvenCell之前，2017年至2022年，Ghias先生在全球生物技术开发公司Paragon Biosciences，LLC（“Paragon”）担任投资和投资组合管理执行副总裁。他还曾担任多家Paragon投资组合公司的首席财务和运营官。在Paragon，他推出了四家专注于罕见病的生物技术公司，从早期临床到成功商业推出。从2014年到2017年，Ghias先生在一家特种罕见病公司Marathon Pharmaceuticals，LLC担任首席财务官和企业发展主管，在那里他为公司的商业发布做好了准备，并领导了该公司的成功出售。在其职业生涯的早期，十多年来，他是一名投资银行家，曾在瑞士信贷担任并购团队的高级成员，为医疗保健和生命科学行业的客户和董事会提供战略建议。Ghias先生在巴基斯坦拉合尔管理科学大学获得经济学学士学位，并在圣路易斯华盛顿大学以优异成绩获得工商管理硕士学位。
- Babar Ghias,joins the Company from AvenCell Therapeutics, Inc. ("AvenCell"), a clinical-stage CAR-T company focused on hematologic malignancies, where he served as Chief Financial Officer since 2022. Prior to joining AvenCell, from 2017 to 2022, Mr. Ghias was Executive Vice President of Investments and Portfolio Management at Paragon Biosciences, LLC ("Paragon"), a global biotech development firm. He also served as Chief Financial and Operating Officer for several Paragon portfolio companies. At Paragon, he launched four biotechnology companies focused on rare diseases from early clinical to successful commercial launch. From 2014 to 2017, Mr. Ghias served as Chief Financial Officer and Head of Corporate Development at Marathon Pharmaceuticals, LLC, a specialty rare disease company, where he prepared the company for a commercial launch and led the successful sale of the firm. Earlier in his career, for over a decade, he was an investment banker who served as a senior member of the mergers and acquisitions team at Credit Suisse, providing strategic advice to clients and boards of directors in the healthcare and life sciences industries. Mr. Ghias received his B.S. degree in Economics from Lahore University of Management Sciences in Pakistan and earned his M.B.A. with honors from Washington University in St. Louis.
- Charles K. Gayer
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Helen M. Thackray
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介